Comparison 21.

Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (< 25 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Observed number of pregnancies (all women)	25	11914	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.55, 0.97]
2 Observed number of pregnancies (by risk status)	3	4715	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.50, 1.38]
2.1 High‐risk women	3	1544	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.36, 1.42]
2.2 Low‐risk women	3	3171	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.45, 2.17]
3 Any side effect	11	2464	Risk Ratio (M‐H, Random, 95% CI)	1.31 [1.01, 1.70]
4 Specific side effects	18		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Nausea	13	7948	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.97, 1.24]
4.2 Vomiting	6	6082	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.68, 2.17]
4.3 Headache	6	6329	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.76, 1.22]
4.4 Dizziness	10	3512	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.79, 1.63]
4.5 Fatigue	12	8209	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.86, 1.15]
4.6 Breast tenderness	9	6010	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.64, 1.29]
4.7 Diarrhoea	9	5746	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.68, 1.55]
4.8 Spotting/bleeding after treatment	11	5078	Risk Ratio (M‐H, Fixed, 95% CI)	1.85 [1.55, 2.20]
4.9 Abdominal pain	4	4870	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.78, 1.32]
5 Menses	21		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 Early	7	2136	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.87, 1.36]
5.2 Delay	21	11282	Risk Ratio (M‐H, Random, 95% CI)	1.28 [1.11, 1.47]